



REVIEW

A theoretical model of temperate phages as mediators of gut microbiome dysbiosis [version 1; peer review: 2 approved]

Derek M. Lin ¹, Henry C. Lin^{1,2}

¹Medicine Service, New Mexico VA Health Care System, Albuquerque, New Mexico, USA

²Department of Gastroenterology and Hepatology, University of New Mexico, Albuquerque, New Mexico, USA

v1 **First published:** 01 Jul 2019, 8(F1000 Faculty Rev):997 (<https://doi.org/10.12688/f1000research.18480.1>)
Latest published: 01 Jul 2019, 8(F1000 Faculty Rev):997 (<https://doi.org/10.12688/f1000research.18480.1>)

Abstract

Bacteriophages are the most prominent members of the gut microbiome, outnumbering their bacterial hosts by a factor of 10. Phages are bacteria-specific viruses that are gaining attention as highly influential regulators of the gut bacterial community. Dysregulation of the gut bacterial community contributes to dysbiosis, a microbiome disorder characterized by compositional and functional changes that contribute to disease. A role for phages in gut microbiome dysbiosis is emerging with evidence that the gut phage community is altered in dysbiosis-associated disorders such as colorectal cancer and inflammatory bowel disease. Several recent studies have linked successful fecal microbiota transplantation to uptake of the donor’s gut phage community, offering some insight into why some recipients respond to treatment whereas others do not. Here, we review the literature supporting a role for phages in mediating the gut bacterial community, giving special attention to Western diet dysbiosis as a case study to demonstrate a theoretical phage-based mechanism for the establishment and maintenance of dysbiosis.

Keywords


Bacteriophage, phage, gut, microbiome, virome, western diet, prophage-encoded genes, dysbiosis, fecal microbiota transplant

Open Peer Review

Reviewer Status  

	Invited Reviewers	
	1	2
version 1 published 01 Jul 2019		

F1000 Faculty Reviews are written by members of the prestigious **F1000 Faculty**. They are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

- 1 **Hariom Yadav** , Wake Forest School of Medicine, Winston-Salem, USA
- 2 **Deanna L Gibson**, University of British Columbia, Kelowna, Canada

Any comments on the article can be found at the end of the article.

Corresponding author: Henry C. Lin (helin@salud.unm.edu)

Author roles: **Lin DM:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Lin HC:** Funding Acquisition, Project Administration, Supervision, Writing – Review & Editing

Competing interests: The authors have intellectual property rights in areas related to bacteriophages and gut microbiome dysbiosis.

Grant information: This study was supported in part by the Winkler Bacterial Overgrowth Research Fund.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Lin DM and Lin HC. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Lin DM and Lin HC. **A theoretical model of temperate phages as mediators of gut microbiome dysbiosis [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):997 (<https://doi.org/10.12688/f1000research.18480.1>)

First published: 01 Jul 2019, 8(F1000 Faculty Rev):997 (<https://doi.org/10.12688/f1000research.18480.1>)

Introduction

Insights into the relationship between diet and the gut microbiome have significantly advanced our understanding of nutrition as a mediator of health and disease. The influence of the Western diet specifically on dysbiosis in the gut bacterial community is well established¹. Conspicuously lacking from this body of research is a fundamental understanding of the gut virome, sometimes referred to as the “dark matter” of the microbiome². It has long been known that the virome harbors genes for antibiotic resistance and bacterial toxins^{3,4}, contributing to the virulence of clinically relevant bacterial pathogens^{5,6}. Emerging evidence implicates an altered gut virome in colorectal cancer, inflammatory bowel disease, and other states associated with microbiome dysbiosis⁷⁻¹⁰. The role of the virome, whether as cause or consequence of dysbiosis, is unclear.

Gut microbiome dysbiosis

Gut microbiome dysbiosis broadly encompasses the various states of perturbed gut microbial community composition associated with disease or disorder in the host. In a healthy gut environment, the resident (commensal) gut bacteria (that is, symbionts) are non-pathogenic. A healthy gut microbiota–host interaction is a mutualism in which gut bacteria thrive in the gastrointestinal environment of the host while providing the host with multiple benefits through metabolism, immune system development, and protection from pathogens¹¹. During dysbiosis, the homeostatic balance of this symbiosis shifts, disrupting the beneficial nature of the relationship and contributing to disease states. In this setting, otherwise beneficial gut symbionts may transition to a state of pathogenicity (that is, pathobionts). Dysbiosis is implicated in the etiology of numerous clinical disorders ranging from those involving the digestive tract, such as inflammatory bowel disease and non-alcoholic steatohepatitis, to those outside the digestive tract, such as atherosclerotic cardiovascular disease and autism¹²⁻¹⁵.

The gut virome

Evidence on the role of gut viruses during dysbiosis is limited. The predominant members of the gut virome are bacteria-specific viruses called bacteriophages (phages). Phages are most commonly associated with phage therapy, a practice of administering lytic phages to control bacterial pathogens (for example, *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*)¹⁶. About 10¹⁴ viruses, comprised of about 1200 virotypes, reside in the gut¹⁷; this population is 10 times as abundant as gut bacteria but comparable in diversity^{18,19}. Contemporary studies of the gut bacterial community rely on next-generation sequencing of the universal 16S rRNA bacterial gene, which provides a compositional readout of the microbiome. This approach is not possible with phages as they lack a conserved phylogenetic marker²⁰, one of many challenges in phage research. Even the gold standard for studying phage communities, viral metagenomics, is limited by the lack of a genomic library to compare against the enormous diversity of uncharacterized phage genes collectively referred to as “viral dark matter”².

Advances in gut phage research have demonstrated a role for phages as agents of compositional change in the gut microbial

community^{21,22}. Phages exert enormous evolutionary pressure on microbial communities by lysing their bacterial hosts or by mediating gene transfer²³. In oceanic surface waters, phage-mediated lysis leads to the death of 20 to 40% of the total bacterial population every 24 hours²⁴. In the gut, phages are primarily temperate and able to incorporate into the bacterial chromosome as latent prophages, thereby reproducing with the bacterial host (that is, the lysogenic cycle); prophages then may produce phage progeny by inducing the lytic cycle (Figure 1)²⁰. Temperate phages also have the option of reproducing by entering the lytic cycle directly and immediately lysing their bacterial host. About half of all sequenced bacterial genomes in the GenBank database contain at least one prophage, and some species can harbor up to 15²⁵. Prophages are intimately linked to bacterial resilience and function, encoding genes for metabolism, antibacterial resistance, and toxin production (for example, shiga toxin production), thereby providing fitness benefits for the bacterial host^{6,9}. Prophages further enhance fitness in their bacterial hosts by preventing infection from other phages (that is, superinfection exclusion) and by lysing competing bacteria (that is, “kill-the-relative”)^{26,27}. Some phage-encoded genes are required for commensal gut bacteria to form a mutualism with their host²⁸; conversely, phage-encoded virulence factors promote pathogenic behavior in their host^{6,29}. These findings are highly relevant to the study of gut microbiome dysbiosis, which can be characterized by the transition of commensal bacteria from symbiont to pathobiont. The transition to dysbiosis is multifactorial and once established it becomes difficult to treat³⁰.

A role for phages in mediating dysbiosis

Dysbiosis is associated with an increased abundance and richness of the mucosal temperate phage population^{7-9,31,32}. Prophages in the gut are spontaneously induced into the lytic cycle at a modest baseline level³³. Large-scale induction typically requires environmental stressors that cause a community-wide “SOS response” in the bacterial hosts³⁴. The SOS response is triggered by DNA damage in the bacterial chromosome³⁵, essentially signaling to the prophage that the bacterial host is no longer suitable. The prophage reacts by inducing the lytic cycle to produce a new population of phage progeny, which seek out new hosts to infect. The inflamed gut is associated with an upregulated SOS response in resident gut bacteria³⁶, loss of phage diversity³², and elevated levels prophage induction³⁷. Elevated prophage induction is a mechanism of horizontal gene transfer between bacterial hosts, increasing rates of genetic recombination and diversification of phage-encoded genes³⁸. This process has been found to drive the evolution of bacterial pathogens by expanding the reservoir of phage-encoded genes for virulence factors and antibiotic resistance^{5,37}. In the setting of an infection by enteric pathogens such as shiga toxin-producing *E. coli*, antibiotics that trigger the SOS response activate shiga toxin synthesis through the phage induction pathway; this can lead to diarrhea, hemorrhagic colitis, hemolytic-uremic syndrome, and even death⁶. Prophages encode virulence factors for other clinically relevant pathogens, including *Vibrio cholerae*, *S. aureus*, *Corynebacterium diphtheriae*, and *Clostridium botulinum*²⁹. In addition to directly encoding genes for toxins, phage genes can indirectly upregulate production of




Figure 1. Reproductive life cycles of a temperate phage. Temperate phages can reproduce via both lytic and lysogenic cycles. The decision as to which cycle gets induced depends on environmental factors. This simplified version of phage life cycles demonstrates how the cycles are intertwined.

bacterial toxins and can influence adhesion, colonization, and invasion³⁹.

Within the gut environment, phages are suspected of mediating diversification of the non-pathogenic, commensal microbial community⁴⁰. Temperate phages are theorized to act on the commensal microbiota via “community shuffling”, whereby prophage induction in response to SOS-triggering stressors may increase the pathobiont-to-symbiont ratio observed during dysbiosis⁴¹. Lending support to this theory is the finding that changes to gut phage community composition precede the onset of type 1 diabetes in children⁴². Furthermore, recovery from *Clostridium difficile* dysbiosis after fecal microbiota transplantation (FMT) is associated with an uptake of the donor phage community^{43–45}. Collectively, there is strong evidence of a role for gut phages in numerous disease states associated with gut microbiome dysbiosis.

Western diet dysbiosis as a case study

A Western diet, characterized by a high-fat, high-sugar, and low-fiber intake, is one of the most clinically important disruptors of the gut microbiome. The substantial body of literature on the Western diet provides an ideal case study for this theoretical model, illustrating the potential role of phages in mediating dysbiosis (a graphical representation of this model can be found

in Figure 2). It should be noted that a “Western” diet is often generalized as “high fat” when it has been shown that the type of fat is an important factor in the onset of dysbiosis and disease^{46,47}. Indeed, a Western diet can be classified differently but is commonly associated with high levels of either n-6 polyunsaturated fats or saturated fats¹.

In a Western diet–induced mouse model of obesity, adverse effects include glucose intolerance and fatty liver, both of which improve after treatment with norfloxacin and ampicillin⁴⁸, demonstrating the role of an antibiotic-sensitive microbiome. Antibiotic treatment reverses the state of increased intestinal permeability, a common outcome of a Western diet that results in elevated plasma concentration of bacterial endotoxins⁴⁹. These findings suggest that a Western diet can disrupt homeostatic balance in the gut microbiome, promoting a state of increased intestinal permeability, increased endotoxin absorption, and endotoxemia. The endotoxin, in turn, drives the immune response of the host, thereby producing inflammation, glucose intolerance, and the other characteristic features of metabolic syndrome.

A Western diet is distinguished by not only its high lipid content but also its low availability of fiber. Deprived of fiber from the diet, the gut microbiota compensates by foraging host glycans from the epithelial mucus layer⁵⁰. Whether phages




Figure 2. Theoretical model for phage-mediated dysbiosis. Prophages can drive otherwise commensal bacterial hosts (symbionts) to behave pathogenically (pathobionts) when exposed to environmental stressors, such as those associated with a Western diet. Phage-encoded genes support bacterial mechanisms for bacterial survival at the cost of the human host. The pathogenic behavior of these resident gut microbes promotes inflammation in the intestinal epithelium, which perpetuates the state of environmental stress and persistent dysbiosis.

mediate genes related to glycan foraging has yet to be studied. A healthy mucus layer is a protective boundary separating the sensitive host epithelium from the pro-inflammatory contents of the intestinal lumen (for example, bacterial endotoxins). Degradation of the mucus layer by glycan-foraging bacteria depletes this protection, bringing luminal bacteria closer to the epithelium, thus promoting inflammation and increased intestinal permeability^{51,52}. A more permeable intestinal lining is hypothesized to allow more oxygen from the bloodstream to enter the normally anoxic intestinal lumen⁵³, inflicting oxidative stress on obligate anaerobes in the gut⁵⁴. This idea is supported by the finding that oxygen respiration becomes a dominant metabolic signature in mouse models of colitis⁵⁵. Using the phosphorescence quenching method, Albenberg *et al.* (2014) showed that there is an oxygen gradient radially in the gut lumen whereby the oxygen concentration is highest near the mucosa⁵⁶. Accordingly, the composition of the gut bacterial community is organized radially, and mucosally associated bacteria are the most oxygen-tolerant⁵⁷. It is now appreciated that the intestinal barrier does not simply have two states, impermeable and permeable, but rather there exists degrees of permeability. However, there is a consensus that increased permeability associated with bacterial translocation and immune activation is harmful and leads to chronic inflammation^{11,53}. A change in oxygen concentration may also affect the gut phage population as oxidative stress is a trigger of the SOS response and can induce prophages to enter the lytic cycle. In support of this hypothesis is a study by Kim and Bae (2016), who demonstrated that a Western diet expands phage-encoded genes for oxidative tolerance⁹. It is unlikely that oxidative stress on commensal bacteria is solely responsible for inducing gut phages, as the metabolic by-products of a Western diet have also been shown to trigger prophage induction⁵⁸.

A Western diet has been found to increase the population density of phages in the gut mucosa and expand the reservoir of phage-encoded genes for phage reproduction⁹. Higher rates of temperate phage infection can cause pathogenicity in commensal gut bacteria by disrupting the function of bacterial genes²⁹. Systematic disruption of bacterial genes by phages may have the potential to drive the entire gut microbial community toward a state of increased pathogenic potential (that is, dysbiosis). Whether other disruptors of the gut microbiome—including antibiotic therapy, inflammation, exposure to anesthesia, surgery or other traumas, immune deficiency, and exposure to toxins—exert their effects on the microbiome via its phage population remains to be tested.

Most laboratory observations suggest that phages generally have a narrow host range (all bacteria a phage can infect)²³, although recent evidence suggests that phages have a much broader host range in the gut than what has been observed *in vitro*^{59,60}. Stressors that induce prophages (for example, antibiotic treatment) consequently broaden phage host range and expand the reservoir of phage-encoded genes for surviving the stressor (for example, antibiotic resistance genes)⁵. Diet is a potential regulator of prophage induction among commensal gut bacteria⁵⁹, and unregulated prophage induction may be

responsible for disturbing the homeostatic relationship between microbiome and host. Since perturbation of the gut environment by a Western diet upregulates phage-encoded genes for lipid metabolism and oxidative tolerance⁹, it can be reasonably postulated that these phages likely confer a competitive advantage to their bacterial hosts in a gut environment with higher availability of lipids and increased levels of luminal oxygen. Phages with the combination of broad host range and genes for bacterial host fitness may have a substantial competitive advantage in the gut microbial community, thereby propagating these genes across taxonomically distinct bacterial species within the microbiota and increasing competition for limited resources such as host glycans from the mucus layer. The microbiome composition during Western diet dysbiosis shifts with an expansion of bacteria in the phyla *Proteobacteria* and *Firmicutes*⁶¹; *Proteobacteria* specifically are associated with numerous dysbioses, intestinal barrier dysfunction, and low-grade inflammation⁵⁷. The majority of gut prophages are found in the genomes of these two phyla⁵⁹, and there is a positive correlation between viral content and *Firmicutes* in the feces during obesity⁶².

There is clear evidence that prophages can help make the decision for their bacterial hosts to act as either symbionts or pathobionts^{6,28} and consumption of a Western diet may influence that decision. Outlined above is one possible mechanism for the evolution of a phage community that promotes pathogen-like behavior in otherwise commensal gut bacteria through elevated prophage induction, wherein bacterial survival may come at a cost to the human host. This theoretical model also takes into account the loss of phage diversity observed in response to gut microbiome perturbations, which may be responsible for the persistence of dysbiosis and resistance to clinical treatment. It is worth noting that our proposed model is not mutually exclusive with other mechanisms that may lead to Western diet-associated dysbiosis, such as those involving host metabolism in response to specific dietary fats⁴⁷ or host genetic factors^{63,64}.

Moving forward

As demonstrated by Howe *et al.* (2016), a Western diet mouse model reduces both bacterial and phage diversity⁶⁵. After mice are transitioned back to a standard diet, diversity of the bacterial community returns to pre-Western diet levels whereas the diversity of the phage community remains low. It is possible that dietary disturbances permanently alter phage diversity as well as the functional nature of the phage-encoded gene reservoir; the long-term impacts of this lost diversity are unknown. Treatment of dysbiosis may be contingent on re-establishing a healthy phage community.

Recent developments in clinical FMT therapy have identified an association between successful treatment of *C. difficile* infection and uptake of the donor's fecal phage community by the FMT recipient^{43,45}. A clinical study found that administration of a bacteria-depleted fecal filtrate (phages retained) was sufficient for treatment of *C. difficile* infection and transition of the recipient phage community toward that of the donor⁴⁴. In

an ulcerative colitis mouse model, FMT responders had reduced populations of mucosal phages compared with non-responders³¹. The composition of the donor's phage community has yet to be considered an important factor for FMT. For that matter, the recipient's diet has also not been considered. Gut phages heavily influence the composition of the gut microbiota and in turn its relationship with the human host. Much research still needs to be carried out to determine how the phage community responds to perturbation and contributes to the establishment, maintenance, and remediation of dysbiosis.

Abbreviation

FMT, fecal microbiota transplantation

Grant information

This study was supported in part by the Winkler Bacterial Overgrowth Research Fund.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References



- Martinez KB, Leone V, Chang EB: **Western diets, gut dysbiosis, and metabolic diseases: Are they linked?** *Gut Microbes*. 2017; **8**(2): 130–42. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Shkoporov AN, Hill C: **Bacteriophages of the Human Gut: The "Known Unknown" of the Microbiome.** *Cell Host Microbe*. 2019; **25**(2): 195–209. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Berg DE, Davies J, Allet B, *et al.*: **Transposition of R factor genes to bacteriophage lambda.** *Proc Natl Acad Sci U S A*. 1975; **72**(9): 3628–32. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Smith HW, Green P, Parsell Z: **Vero cell toxins in Escherichia coli and related bacteria: transfer by phage and conjugation and toxic action in laboratory animals, chickens and pigs.** *J Gen Microbiol*. 1983; **129**(10): 3121–37. [PubMed Abstract](#) | [Publisher Full Text](#)
- Modi SR, Lee HH, Spina CS, *et al.*: **Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome.** *Nature*. 2013; **499**(7457): 219–22. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Zhang X, McDaniel AD, Wolf LE, *et al.*: **Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.** *J Infect Dis*. 2000; **181**(2): 664–70. [PubMed Abstract](#) | [Publisher Full Text](#)
- Norman JM, Handley SA, Baldrige MT, *et al.*: **Disease-specific alterations in the enteric virome in inflammatory bowel disease.** *Cell*. 2015; **160**(3): 447–60. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Lepage P, Colombet J, Marteau P, *et al.*: **Dysbiosis in inflammatory bowel disease: a role for bacteriophages?** *Gut*. 2008; **57**(3): 424–5. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kim MS, Bae JW: **Spatial disturbances in altered mucosal and luminal gut viromes of diet-induced obese mice.** *Environ Microbiol*. 2016; **18**(5): 1498–510. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Nakatsu G, Zhou H, Wu WKK, *et al.*: **Alterations in Enteric Virome Are Associated With Colorectal Cancer and Survival Outcomes.** *Gastroenterology*. 2018; **155**(2): 529–541.e5. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- DeGruttola AK, Low D, Mizoguchi A, *et al.*: **Current Understanding of Dysbiosis in Disease in Human and Animal Models.** *Inflamm Bowel Dis*. 2016; **22**(5): 1137–50. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Tamboli CP, Neut C, Desreumaux P, *et al.*: **Dysbiosis in inflammatory bowel disease.** *Gut*. 2004; **53**(1): 1–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Henaoui-Mejia J, Elinav E, Jin C, *et al.*: **Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.** *Nature*. 2012; **482**(7384): 179–85. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Serino M, Blasco-Baque V, Nicolas S, *et al.*: **Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences.** *Curr Cardiol Rep*. 2014; **16**(11): 540. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Williams BL, Hornig M, Buie T, *et al.*: **Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances.** *PLoS One*. 2011; **6**(9): e24585. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lin DM, Koskella B, Lin HC: **Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.** *World J Gastrointest Pharmacol Ther*. 2017; **8**(3): 162–173. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Breitbart M, Hewson I, Felts B, *et al.*: **Metagenomic analyses of an uncultured viral community from human feces.** *J Bacteriol*. 2003; **185**(20): 6220–3. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sender R, Fuchs S, Milo R: **Revised Estimates for the Number of Human and Bacteria Cells in the Body.** *PLoS Biol*. 2016; **14**(8): e1002533. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Lozupone CA, Stombaugh JI, Gordon JI, *et al.*: **Diversity, stability and resilience of the human gut microbiota.** *Nature*. 2012; **489**(7415): 220–30. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Reyes A, Semenovich NP, Whiteson K, *et al.*: **Going viral: next-generation sequencing applied to phage populations in the human gut.** *Nat Rev Micro*. 2012; **10**(9): 607–17. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bao HD, Pang MD, Olaniran A, *et al.*: **Alterations in the diversity and composition of mice gut microbiota by lytic or temperate gut phage treatment.** *Appl Microbiol Biotechnol*. 2018; **102**(23): 10219–30. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Hsu BB, Gibson TE, Yeliseyev V, *et al.*: **Bacteriophages dynamically modulate the gut microbiota and metabolome.** *bioRxiv*. 2018. [PubMed Abstract](#) | [F1000 Recommendation](#)
- Koskella B, Brockhurst MA: **Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities.** *FEMS Microbiol Rev*. 2014; **38**(5): 916–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Suttle CA: **The significance of viruses to mortality in aquatic microbial communities.** *Microb Ecol*. 1994; **28**(2): 237–43. [PubMed Abstract](#) | [Publisher Full Text](#)
- Touchon M, Bernheim A, Rocha EP: **Genetic and life-history traits associated with the distribution of prophages in bacteria.** *ISME J*. 2016; **10**(11): 2744–54. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- De Paepe M, Leclerc M, Tinsley CR, *et al.*: **Bacteriophages: an underestimated role in human and animal health?** *Front Cell Infect Microbiol*. 2014; **4**: 39. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bondy-Denomy J, Qian J, Westra ER, *et al.*: **Prophages mediate defense against phage infection through diverse mechanisms.** *ISME J*. 2016; **10**(12): 2854–66. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Oliver KM, Degnan PH, Hunter MS, *et al.*: **Bacteriophages encode factors required for protection in a symbiotic mutualism.** *Science*. 2009; **325**(5943): 992–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brüssow H, Canchaya C, Hardt WD: **Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion.** *Microbiol Mol Biol Rev*. 2004; **68**(3): 560–602. table of contents. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Weiss GA, Hennes T: **Mechanisms and consequences of intestinal dysbiosis.** *Cell Mol Life Sci*. 2017; **74**(16): 2959–77. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Gogokhia L, Buhrke K, Bell R, *et al.*: **Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.** *Cell Host Microbe*. 2019; **25**(2): 285–299.e8. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Zuo T, Lu XJ, Zhang Y, *et al.*: **Gut mucosal virome alterations in ulcerative colitis.** *Gut*. 2019; **68**(7): 1169–1179. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Reyes A, Wu M, McNulty NP, *et al.*: **Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut.** *Proc Natl Acad Sci U S A*. 2013; **110**(50):

- 20236–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. **F** Allen HK, Looft T, Bayles DO, *et al.*: **Antibiotics in feed induce prophages in swine fecal microbiomes.** *mBio*. 2011; 2(6): pii: e00260-11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. Dwyer DJ, Kohanski MA, Collins JJ: **Role of reactive oxygen species in antibiotic action and resistance.** *Curr Opin Microbiol*. 2009; 12(5): 482–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Butala M, Zgur-Bertok D, Busby SJ: **The bacterial LexA transcriptional repressor.** *Cell Mol Life Sci*. 2009; 66(1): 82–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. **F** Diard M, Bakkeren E, Cornuault JK, *et al.*: **Inflammation boosts bacteriophage transfer between *Salmonella* spp.** *Science*. 2017; 355(6330): 1211–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
38. **F** Touchon M, Moura de Sousa JA, Rocha EP: **Embracing the enemy: the diversification of microbial gene repertoires by phage-mediated horizontal gene transfer.** *Curr Opin Microbiol*. 2017; 38: 66–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Wagner PL, Waldor MK: **Bacteriophage control of bacterial virulence.** *Infect Immun*. 2002; 70(8): 3985–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. **F** Scanlan PD: **Bacteria-Bacteriophage Coevolution in the Human Gut: Implications for Microbial Diversity and Functionality.** *Trends Microbiol*. 2017; 25(8): 614–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
41. Mills S, Shanahan F, Stanton C, *et al.*: **Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota.** *Gut Microbes*. 2013; 4(1): 4–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. **F** Zhao G, Vatanen T, Droit L, *et al.*: **Intestinal virome changes precede autoimmunity in type I diabetes-susceptible children.** *Proc Natl Acad Sci U S A*. 2017; 114(30): E6166–E6175.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
43. **F** Chehoud C, Dryga A, Hwang Y, *et al.*: **Transfer of Viral Communities between Human Individuals during Fecal Microbiota Transplantation.** *mBio*. 2016; 7(2): e00322.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. **F** Ott SJ, Waetzig GH, Rehman A, *et al.*: **Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With *Clostridium difficile* Infection.** *Gastroenterology*. 2017; 152(4): 799–811.e7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
45. **F** Zuo T, Wong SH, Lam K, *et al.*: **Bacteriophage transfer during faecal microbiota transplantation in *Clostridium difficile* infection is associated with treatment outcome.** *Gut*. 2018; 67(4): 634–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
46. **F** Huang EY, Leone VA, Devkota S, *et al.*: **Composition of dietary fat source shapes gut microbiota architecture and alters host inflammatory mediators in mouse adipose tissue.** *JPEN J Parenter Enteral Nutr*. 2013; 37(6): 746–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
47. **F** Devkota S, Wang Y, Musch MW, *et al.*: **Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10-/- mice.** *Nature*. 2012; 487(7405): 104–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
48. Membrez M, Blancher F, Jaquet M, *et al.*: **Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice.** *FASEB J*. 2008; 22(7): 2416–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Cani PD, Bibiloni R, Knauf C, *et al.*: **Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.** *Diabetes*. 2008; 57(6): 1470–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. **F** Desai MS, Seekatz AM, Koropatkin NM, *et al.*: **A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility.** *Cell*. 2016; 167(5): 1339–1353.e21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
51. Kim YS, Ho SB: **Intestinal goblet cells and mucins in health and disease: recent insights and progress.** *Curr Gastroenterol Rep*. 2010; 12(5): 319–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Johansson ME, Gustafsson JK, Sjöberg KE, *et al.*: **Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model.** *PLoS One*. 2010; 5(8): e12238.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Rigottier-Gois L: **Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis.** *ISME J*. 2013; 7(7): 1256–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. **F** Zeng MY, Inohara N, Nuñez G: **Mechanisms of inflammation-driven bacterial dysbiosis in the gut.** *Mucosal Immunol*. 2017; 10(1): 18–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. **F** Hughes ER, Winter MG, Duerkop BA, *et al.*: **Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis.** *Cell Host Microbe*. 2017; 21(2): 208–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
56. Albenberg L, Espipova TV, Judge CP, *et al.*: **Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota.** *Gastroenterology*. 2014; 147(5): 1055–63.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. **F** Litvak Y, Byndloss MX, Tsois RM, *et al.*: **Dysbiotic *Proteobacteria* expansion: a microbial signature of epithelial dysfunction.** *Curr Opin Microbiol*. 2017; 39: 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
58. **F** Oh JH, Alexander LM, Pan M, *et al.*: **Dietary Fructose and Microbiota-Derived Short-Chain Fatty Acids Promote Bacteriophage Production in the Gut Symbiont *Lactobacillus reuteri*.** *Cell Host Microbe*. 2019; 25(2): 273–284.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
59. **F** Kim MS, Bae JW: **Lysogeny is prevalent and widely distributed in the murine gut microbiota.** *ISME J*. 2018; 12(4): 1127–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. Ogilvie LA, Jones BV: **The human gut virome: a multifaceted majority.** *Front Microbiol*. 2015; 6: 918.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. **F** Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, *et al.*: **High-fat diet determines the composition of the murine gut microbiome independently of obesity.** *Gastroenterology*. 2009; 137(5): 1716–1724.e2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
62. **F** Yadav H, Jain S, Nagpal R, *et al.*: **Increased fecal viral content associated with obesity in mice.** *World J Diabetes*. 2016; 7(15): 316–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
63. **F** Kostic AD, Gevers D, Siljander H, *et al.*: **The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes.** *Cell Host Microbe*. 2015; 17(2): 260–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
64. **F** Knights D, Silverberg MS, Weersma RK, *et al.*: **Complex host genetics influence the microbiome in inflammatory bowel disease.** *Genome Med*. 2014; 6(12): 107.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
65. **F** Howe A, Ringus DL, Williams RJ, *et al.*: **Divergent responses of viral and bacterial communities in the gut microbiome to dietary disturbances in mice.** *ISME J*. 2016; 10(5): 1217–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:  

Editorial Note on the Review Process

F1000 Faculty Reviews are written by members of the prestigious F1000 Faculty. They are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1 **Deanna L Gibson**

Department of Biology, University of British Columbia, Kelowna, BC, Canada

Competing Interests: No competing interests were disclosed.

2 **Hariom Yadav** 

Department of Internal Medicine-Molecular Medicine and Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research